DK3389699T5 - Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf - Google Patents
Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK3389699T5 DK3389699T5 DK16876612.9T DK16876612T DK3389699T5 DK 3389699 T5 DK3389699 T5 DK 3389699T5 DK 16876612 T DK16876612 T DK 16876612T DK 3389699 T5 DK3389699 T5 DK 3389699T5
- Authority
- DK
- Denmark
- Prior art keywords
- chimeric
- monoclonal antibodies
- humanized anti
- human ctla4
- ctla4 monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267735P | 2015-12-15 | 2015-12-15 | |
| US201662309169P | 2016-03-16 | 2016-03-16 | |
| US201662359036P | 2016-07-06 | 2016-07-06 | |
| PCT/US2016/066698 WO2017106372A1 (en) | 2015-12-15 | 2016-12-14 | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3389699T3 DK3389699T3 (da) | 2024-05-13 |
| DK3389699T5 true DK3389699T5 (da) | 2024-09-23 |
Family
ID=59057509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16876612.9T DK3389699T5 (da) | 2015-12-15 | 2016-12-14 | Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10618960B2 (enExample) |
| EP (2) | EP4374926A3 (enExample) |
| JP (4) | JP6858779B2 (enExample) |
| KR (2) | KR20250108763A (enExample) |
| CN (2) | CN116063492A (enExample) |
| AU (2) | AU2016370648B2 (enExample) |
| BR (1) | BR112018012113A2 (enExample) |
| CA (1) | CA3006984C (enExample) |
| DK (1) | DK3389699T5 (enExample) |
| ES (1) | ES2979210T3 (enExample) |
| FI (1) | FI3389699T3 (enExample) |
| HR (1) | HRP20240719T1 (enExample) |
| HU (1) | HUE066907T2 (enExample) |
| IL (3) | IL296354B2 (enExample) |
| LT (1) | LT3389699T (enExample) |
| MX (3) | MX2018006925A (enExample) |
| MY (1) | MY186974A (enExample) |
| PL (1) | PL3389699T3 (enExample) |
| PT (1) | PT3389699T (enExample) |
| RS (1) | RS65703B1 (enExample) |
| SG (1) | SG11201804969PA (enExample) |
| SI (1) | SI3389699T1 (enExample) |
| SM (1) | SMT202400211T1 (enExample) |
| TW (1) | TWI739781B (enExample) |
| WO (1) | WO2017106372A1 (enExample) |
| ZA (1) | ZA201804077B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| CA3036997A1 (en) | 2016-09-19 | 2018-03-22 | Oncoimmune, Inc. | Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| AU2018366199A1 (en) * | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| SG11202007018QA (en) * | 2018-02-02 | 2020-08-28 | Oncoimmune Inc | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| SG11202007017PA (en) * | 2018-02-02 | 2020-08-28 | Oncoimmune Inc | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| CN112399973B (zh) * | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CA3123338A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| CN119930820A (zh) * | 2018-12-27 | 2025-05-06 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| JP7440724B2 (ja) * | 2020-04-13 | 2024-02-29 | ビオシオン インコーポレイテッド | Ｃｔｌａ４に結合する抗体及びその使用 |
| US20230167153A1 (en) | 2020-05-01 | 2023-06-01 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| US20240182571A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| JP7345889B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| AU2022359021A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| CA3234496A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| KR20240091042A (ko) * | 2021-10-29 | 2024-06-21 | 롱바이오 파마 (수조우) 컴퍼니 리미티드 | 분리된 항원 결합 단백질 및 이의 용도 |
| TW202325738A (zh) * | 2021-10-29 | 2023-07-01 | 美商昂科Ｃ４公司 | 抗ctla-4抗體給藥方案 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| JP2025531229A (ja) | 2022-09-16 | 2025-09-19 | オンコシーフォー、インク． | 腺様嚢胞がんを処置するための抗ｃｔｌａ－４抗体の使用 |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200826A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof |
| AU2024262223A1 (en) | 2023-04-28 | 2025-11-27 | Acroimmune Biopharma Co., Ltd. | Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof |
| WO2024254403A2 (en) * | 2023-06-09 | 2024-12-12 | The Regents Of The University Of California | Methods for identifying and correcting tumor humoral immune dysfunction |
| WO2025133186A1 (en) | 2023-12-22 | 2025-06-26 | OncoC4, Inc. | Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JP5004390B2 (ja) | 1999-08-23 | 2012-08-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 新規ｂ７−４分子およびその用途 |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| JP2003520828A (ja) * | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20080152655A1 (en) * | 2004-09-08 | 2008-06-26 | The Ohio State University Research Foundation | Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| CA2583741C (en) | 2004-10-15 | 2014-10-14 | Verisign, Inc. | An algorithm to create and validate a one time password |
| DK1853631T3 (en) | 2005-01-24 | 2016-03-29 | Univ Texas | Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF |
| CN109485727A (zh) * | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| CN101628940B (zh) * | 2008-07-15 | 2011-11-23 | 中国科学院生物物理研究所 | 一种单克隆抗体及其应用 |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| US20150079100A1 (en) * | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
| DK2925350T3 (da) * | 2012-12-03 | 2019-05-13 | Bristol Myers Squibb Co | Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner |
| WO2014209804A1 (en) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| CA3036997A1 (en) | 2016-09-19 | 2018-03-22 | Oncoimmune, Inc. | Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy |
-
2016
- 2016-12-14 DK DK16876612.9T patent/DK3389699T5/da active
- 2016-12-14 HU HUE16876612A patent/HUE066907T2/hu unknown
- 2016-12-14 JP JP2018530560A patent/JP6858779B2/ja active Active
- 2016-12-14 KR KR1020257022200A patent/KR20250108763A/ko active Pending
- 2016-12-14 CN CN202210802423.XA patent/CN116063492A/zh active Pending
- 2016-12-14 US US16/062,350 patent/US10618960B2/en active Active
- 2016-12-14 SI SI201631826T patent/SI3389699T1/sl unknown
- 2016-12-14 EP EP24164173.7A patent/EP4374926A3/en active Pending
- 2016-12-14 IL IL296354A patent/IL296354B2/en unknown
- 2016-12-14 ES ES16876612T patent/ES2979210T3/es active Active
- 2016-12-14 KR KR1020187017368A patent/KR102830926B1/ko active Active
- 2016-12-14 BR BR112018012113A patent/BR112018012113A2/pt active Search and Examination
- 2016-12-14 RS RS20240735A patent/RS65703B1/sr unknown
- 2016-12-14 LT LTEPPCT/US2016/066698T patent/LT3389699T/lt unknown
- 2016-12-14 WO PCT/US2016/066698 patent/WO2017106372A1/en not_active Ceased
- 2016-12-14 HR HRP20240719TT patent/HRP20240719T1/hr unknown
- 2016-12-14 PL PL16876612.9T patent/PL3389699T3/pl unknown
- 2016-12-14 FI FIEP16876612.9T patent/FI3389699T3/fi active
- 2016-12-14 CA CA3006984A patent/CA3006984C/en active Active
- 2016-12-14 SG SG11201804969PA patent/SG11201804969PA/en unknown
- 2016-12-14 IL IL259988A patent/IL259988B2/en unknown
- 2016-12-14 EP EP16876612.9A patent/EP3389699B1/en active Active
- 2016-12-14 IL IL310404A patent/IL310404A/en unknown
- 2016-12-14 PT PT168766129T patent/PT3389699T/pt unknown
- 2016-12-14 MX MX2018006925A patent/MX2018006925A/es unknown
- 2016-12-14 MY MYPI2018000904A patent/MY186974A/en unknown
- 2016-12-14 AU AU2016370648A patent/AU2016370648B2/en active Active
- 2016-12-14 CN CN201680073425.2A patent/CN108430499B/zh active Active
- 2016-12-14 SM SM20240211T patent/SMT202400211T1/it unknown
- 2016-12-15 TW TW105141656A patent/TWI739781B/zh active
-
2018
- 2018-06-07 MX MX2025001302A patent/MX2025001302A/es unknown
- 2018-06-07 MX MX2025001300A patent/MX2025001300A/es unknown
- 2018-06-18 ZA ZA2018/04077A patent/ZA201804077B/en unknown
-
2020
- 2020-02-27 US US16/803,972 patent/US11629188B2/en active Active
-
2021
- 2021-03-23 JP JP2021049294A patent/JP2021100957A/ja active Pending
-
2022
- 2022-06-15 JP JP2022096901A patent/JP7286845B2/ja active Active
-
2023
- 2023-03-22 US US18/188,098 patent/US12473362B2/en active Active
- 2023-05-19 AU AU2023203169A patent/AU2023203169B2/en active Active
-
2025
- 2025-08-04 JP JP2025130097A patent/JP2025160458A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3389699T5 (da) | Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf | |
| IL283812A (en) | Humanized antibody against human pd–1 | |
| DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
| DK3356408T3 (da) | Humaniserede anti-humane CD19-antistoffer og fremgangsmåder til anvendelse | |
| DK4249515T3 (en) | Humanized or chimeric cd3 antibodies | |
| DK3286223T3 (da) | Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf | |
| IL281272A (en) | Humanized antibodies against C5 and their uses | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
| IL263936A (en) | Humanized monoclonal antibodies targeting hptp-beta)ve-ptp) | |
| ZA201701920B (en) | Anti-human il-17 monoclonal antibodies and use thereof | |
| IL282756A (en) | Humanized antibodies against SIRPα | |
| EP3466974A4 (en) | HUMANIZED MONOCLONAL ANTI-HUMAN PD-1 ANTIBODY AND USE THEREOF | |
| ZA201807167B (en) | Humanized anti-il-1r3 antibodies | |
| IL248402A0 (en) | Humanized antibodies against ceacam1 | |
| EP3131917A4 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| ITUB20155097A1 (it) | Anticorpi umanizzati anti-BAG3 | |
| EP3891180C0 (en) | HUMANIZED ANTIBODIES AGAINST IL17BR | |
| EP3955925A4 (en) | HUMANIZED ANTI-PD-L1 ANTIBODIES | |
| HK40092659A (zh) | 嵌合和人源化抗人类ctla4单克隆抗体和其用途 |